Name | Number of supported studies | Average coverage | |
---|---|---|---|
T cell | 6 studies | 28% ± 10% | |
B cell | 5 studies | 26% ± 4% | |
plasmablast | 5 studies | 42% ± 14% | |
epithelial cell | 5 studies | 26% ± 12% | |
transit amplifying cell | 4 studies | 30% ± 1% | |
plasma cell | 4 studies | 26% ± 7% | |
erythrocyte | 4 studies | 33% ± 13% | |
CD4-positive, alpha-beta T cell | 4 studies | 41% ± 7% | |
CD8-positive, alpha-beta T cell | 4 studies | 31% ± 11% | |
erythroblast | 3 studies | 43% ± 23% | |
pro-B cell | 3 studies | 27% ± 5% | |
natural killer cell | 3 studies | 27% ± 1% |
Insufficient scRNA-seq data for expression of BIRC5 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 93% | 1670.15 | 1677 / 1809 | 95% | 49.94 | 449 / 472 |
lung | 68% | 250.90 | 394 / 578 | 87% | 54.97 | 1009 / 1155 |
intestine | 53% | 372.72 | 515 / 966 | 95% | 57.74 | 500 / 527 |
stomach | 48% | 293.13 | 172 / 359 | 95% | 44.64 | 271 / 286 |
esophagus | 44% | 552.98 | 636 / 1445 | 93% | 39.81 | 170 / 183 |
bladder | 19% | 36.86 | 4 / 21 | 94% | 62.90 | 476 / 504 |
breast | 25% | 60.28 | 116 / 459 | 88% | 46.03 | 983 / 1118 |
uterus | 10% | 24.02 | 17 / 170 | 99% | 80.29 | 454 / 459 |
ovary | 8% | 35.43 | 15 / 180 | 95% | 46.65 | 409 / 430 |
liver | 45% | 132.18 | 102 / 226 | 57% | 18.76 | 231 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 75.08 | 29 / 29 |
tonsil | 0% | 0 | 0 / 0 | 100% | 82.43 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 36.71 | 1 / 1 |
spleen | 98% | 734.15 | 235 / 241 | 0% | 0 | 0 / 0 |
pancreas | 10% | 18.62 | 33 / 328 | 69% | 19.89 | 122 / 178 |
peripheral blood | 74% | 1385.60 | 685 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 46% | 117.90 | 119 / 258 | 16% | 5.71 | 37 / 230 |
brain | 6% | 8.58 | 152 / 2642 | 46% | 24.74 | 325 / 705 |
prostate | 29% | 54.86 | 70 / 245 | 21% | 4.38 | 103 / 502 |
kidney | 22% | 81.75 | 20 / 89 | 13% | 3.16 | 117 / 901 |
thymus | 16% | 30.49 | 107 / 653 | 15% | 14.15 | 92 / 605 |
eye | 0% | 0 | 0 / 0 | 29% | 3.89 | 23 / 80 |
adipose | 25% | 67.73 | 301 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 15% | 29.35 | 201 / 1335 | 0% | 0 | 0 / 0 |
heart | 9% | 24.60 | 77 / 861 | 0% | 0 | 0 / 0 |
muscle | 1% | 1.12 | 7 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007605 | Biological process | sensory perception of sound |
GO_0000278 | Biological process | mitotic cell cycle |
GO_1901970 | Biological process | positive regulation of mitotic sister chromatid separation |
GO_0000281 | Biological process | mitotic cytokinesis |
GO_0090307 | Biological process | mitotic spindle assembly |
GO_0051256 | Biological process | mitotic spindle midzone assembly |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0090267 | Biological process | positive regulation of mitotic cell cycle spindle assembly checkpoint |
GO_0006915 | Biological process | apoptotic process |
GO_1902425 | Biological process | positive regulation of attachment of mitotic spindle microtubules to kinetochore |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_1903490 | Biological process | positive regulation of mitotic cytokinesis |
GO_0006468 | Biological process | protein phosphorylation |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0031503 | Biological process | protein-containing complex localization |
GO_0000775 | Cellular component | chromosome, centromeric region |
GO_1990713 | Cellular component | survivin complex |
GO_0030496 | Cellular component | midbody |
GO_0005874 | Cellular component | microtubule |
GO_0000228 | Cellular component | nuclear chromosome |
GO_0000776 | Cellular component | kinetochore |
GO_0005654 | Cellular component | nucleoplasm |
GO_0032133 | Cellular component | chromosome passenger complex |
GO_0005829 | Cellular component | cytosol |
GO_0015630 | Cellular component | microtubule cytoskeleton |
GO_0005737 | Cellular component | cytoplasm |
GO_0005819 | Cellular component | spindle |
GO_0005634 | Cellular component | nucleus |
GO_0004869 | Molecular function | cysteine-type endopeptidase inhibitor activity |
GO_0019899 | Molecular function | enzyme binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0031267 | Molecular function | small GTPase binding |
GO_0051087 | Molecular function | protein-folding chaperone binding |
GO_0008017 | Molecular function | microtubule binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | BIRC5 |
Protein name | Baculoviral IAP repeat-containing protein 5 (Apoptosis inhibitor survivin) Baculoviral IAP repeat-containing protein 5 (Apoptosis inhibitor 4) (Apoptosis inhibitor survivin) |
Synonyms | IAP4 API4 |
Description | FUNCTION: Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis . Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis . Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules . Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis . The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules . May counteract a default induction of apoptosis in G2/M phase . The acetylated form represses STAT3 transactivation of target gene promoters . May play a role in neoplasia . Inhibitor of CASP3 and CASP7 . Essential for the maintenance of mitochondrial integrity and function . Isoform 2 and isoform 3 do not appear to play vital roles in mitosis . Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform . . |
Accessions | A3E0Z6 A3E0Z4 E7CU85 K7ELG2 K7EP76 A0A0B4J1S3 A3E0Z5 A0A7L8XZM3 ENST00000587746.5 ENST00000590925.6 [O15392-4] ENST00000591800.1 A3E0Z7 ENST00000374948.6 [O15392-3] ENST00000350051.8 ENST00000590449.1 [O15392-7] H3BLT4 ENST00000301633.8 O15392 ENST00000586192.5 A3E0Z8 ENST00000592734.5 [O15392-6] K7EMW2 |